Functional C1q deficiency in a systemic lupus erythematosus patient with a concurrent somatic TNFAIP3 variant

Early identification of SLE patients with causative genetic variants may inform precision treatment strategies by revealing actionable biological pathways. In a refractory SLE patient harboring a somatic TNFAIP3 variant, we sought additional pathogenic variants and disease mechanisms. The patient’s medical records were collected. Whole-exome sequencing (WES) and droplet digital polymerase chain reaction (PCR) was performed to detect pathogenic variants and the variant allele frequency. Enzyme-linked immunosorbent assay and C1q reconstitution assay were conducted to assess the complement components. Bulk RNA sequencing and quantitative PCR were performed to explore the activation of inflammatory pathways. A 4-year-old girl with recurrent fever, arthritis, chilblain-like rashes, recurrent seizures, multiple positive autoantibodies and intracranial calcifications was referred to our hospital. Initial WES found a somatic pathogenic TNFAIP3 variant, suggesting the diagnosis of haploinsufficiency of A20 (HA20), which could account for the recurrent fever. However, the patient did not respond well to the first-line TNF inhibitors for HA20, prompting further genetic analysis. And a novel homozygous variant in C1QB was found. Complement assays showed functional C1q deficiency despite normal C1q levels. RNA sequencing revealed strong type I interferon signature in the patient, which was suppressed following treatment with the tyrosine kinase 2 inhibitor deucravacitinib. Fresh frozen plasma (FFP) infusions restored complement hemolytic activity. Combination therapy with FFP and deucravacitinib was associated with clinical stabilization and successful steroid tapering. We report a SLE case due to a novel C1QB variant causing functional C1q deficiency without reducing protein levels, with targeted C1q therapy showing efficacy. The co-existing somatic TNFAIP3 variant might contribute to part of the phenotype, such as recurrent fever.

Authors

Institutions

Publication Details

Journal
BMC Medical Genomics
Published
2026-11-13
DOI
https://doi.org/10.1186/s12920-026-02509-0
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Functional C1q deficiency in a systemic lupus erythematosus patient with a concurrent somatic TNFAIP3 variant

Gexuan Feng, X. Wang, Mingsheng Ma, Shan Jian et al.
1 links
BMC Medical Genomics
Systemic Lupus Erythematosus Research
article

Functional C1q deficiency in a systemic lupus erythematosus patient with a concurrent somatic TNFAIP3 variant

Gexuan Feng, X. Wang, Mingsheng Ma, Shan Jian, Siming Peng, Ting Li, Tianjiao Wang, Yu Zhou, Zhongxun Yu, Hongmei Song, Sihao Gao
article en

Abstract

Early identification of SLE patients with causative genetic variants may inform precision treatment strategies by revealing actionable biological pathways. In a refractory SLE patient harboring a somatic TNFAIP3 variant, we sought additional pathogenic variants and disease mechanisms. The patient’s medical records were collected. Whole-exome sequencing (WES) and droplet digital polymerase chain reaction (PCR) was performed to detect pathogenic variants and the variant allele frequency. Enzyme-linked immunosorbent assay and C1q reconstitution assay were conducted to assess the complement components. Bulk RNA sequencing and quantitative PCR were performed to explore the activation of inflammatory pathways. A 4-year-old girl with recurrent fever, arthritis, chilblain-like rashes, recurrent seizures, multiple positive autoantibodies and intracranial calcifications was referred to our hospital. Initial WES found a somatic pathogenic TNFAIP3 variant, suggesting the diagnosis of haploinsufficiency of A20 (HA20), which could account for the recurrent fever. However, the patient did not respond well to the first-line TNF inhibitors for HA20, prompting further genetic analysis. And a novel homozygous variant in C1QB was found. Complement assays showed functional C1q deficiency despite normal C1q levels. RNA sequencing revealed strong type I interferon signature in the patient, which was suppressed following treatment with the tyrosine kinase 2 inhibitor deucravacitinib. Fresh frozen plasma (FFP) infusions restored complement hemolytic activity. Combination therapy with FFP and deucravacitinib was associated with clinical stabilization and successful steroid tapering. We report a SLE case due to a novel C1QB variant causing functional C1q deficiency without reducing protein levels, with targeted C1q therapy showing efficacy. The co-existing somatic TNFAIP3 variant might contribute to part of the phenotype, such as recurrent fever.

BMC Medical Genomics
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking Union Medical College Hospital (CN)
National Key Research and Development Program of China
Good health and well-being
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon